Cargando…

Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma

PURPOSE: To construct a multi-institutional radiomic model that supports upfront prediction of progression-free survival (PFS) and recurrence pattern (RP) in patients diagnosed with glioblastoma multiforme (GBM) at the time of initial diagnosis. PATIENTS AND METHODS: We retrospectively identified da...

Descripción completa

Detalles Bibliográficos
Autores principales: Fathi Kazerooni, Anahita, Akbari, Hamed, Shukla, Gaurav, Badve, Chaitra, Rudie, Jeffrey D., Sako, Chiharu, Rathore, Saima, Bakas, Spyridon, Pati, Sarthak, Singh, Ashish, Bergman, Mark, Ha, Sung Min, Kontos, Despina, Nasrallah, MacLean, Bagley, Stephen J., Lustig, Robert A., O’Rourke, Donald M., Sloan, Andrew E., Barnholtz-Sloan, Jill S., Mohan, Suyash, Bilello, Michel, Davatzikos, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113126/
https://www.ncbi.nlm.nih.gov/pubmed/32191542
http://dx.doi.org/10.1200/CCI.19.00121
_version_ 1783513602251030528
author Fathi Kazerooni, Anahita
Akbari, Hamed
Shukla, Gaurav
Badve, Chaitra
Rudie, Jeffrey D.
Sako, Chiharu
Rathore, Saima
Bakas, Spyridon
Pati, Sarthak
Singh, Ashish
Bergman, Mark
Ha, Sung Min
Kontos, Despina
Nasrallah, MacLean
Bagley, Stephen J.
Lustig, Robert A.
O’Rourke, Donald M.
Sloan, Andrew E.
Barnholtz-Sloan, Jill S.
Mohan, Suyash
Bilello, Michel
Davatzikos, Christos
author_facet Fathi Kazerooni, Anahita
Akbari, Hamed
Shukla, Gaurav
Badve, Chaitra
Rudie, Jeffrey D.
Sako, Chiharu
Rathore, Saima
Bakas, Spyridon
Pati, Sarthak
Singh, Ashish
Bergman, Mark
Ha, Sung Min
Kontos, Despina
Nasrallah, MacLean
Bagley, Stephen J.
Lustig, Robert A.
O’Rourke, Donald M.
Sloan, Andrew E.
Barnholtz-Sloan, Jill S.
Mohan, Suyash
Bilello, Michel
Davatzikos, Christos
author_sort Fathi Kazerooni, Anahita
collection PubMed
description PURPOSE: To construct a multi-institutional radiomic model that supports upfront prediction of progression-free survival (PFS) and recurrence pattern (RP) in patients diagnosed with glioblastoma multiforme (GBM) at the time of initial diagnosis. PATIENTS AND METHODS: We retrospectively identified data for patients with newly diagnosed GBM from two institutions (institution 1, n = 65; institution 2, n = 15) who underwent gross total resection followed by standard adjuvant chemoradiation therapy, with pathologically confirmed recurrence, sufficient follow-up magnetic resonance imaging (MRI) scans to reliably determine PFS, and available presurgical multiparametric MRI (MP-MRI). The advanced software suite Cancer Imaging Phenomics Toolkit (CaPTk) was leveraged to analyze standard clinical brain MP-MRI scans. A rich set of imaging features was extracted from the MP-MRI scans acquired before the initial resection and was integrated into two distinct imaging signatures for predicting mean shorter or longer PFS and near or distant RP. The predictive signatures for PFS and RP were evaluated on the basis of different classification schemes: single-institutional analysis, multi-institutional analysis with random partitioning of the data into discovery and replication cohorts, and multi-institutional assessment with data from institution 1 as the discovery cohort and data from institution 2 as the replication cohort. RESULTS: These predictors achieved cross-validated classification performance (ie, area under the receiver operating characteristic curve) of 0.88 (single-institution analysis) and 0.82 to 0.83 (multi-institution analysis) for prediction of PFS and 0.88 (single-institution analysis) and 0.56 to 0.71 (multi-institution analysis) for prediction of RP. CONCLUSION: Imaging signatures of presurgical MP-MRI scans reveal relatively high predictability of time and location of GBM recurrence, subject to the patients receiving standard first-line chemoradiation therapy. Through its graphical user interface, CaPTk offers easy accessibility to advanced computational algorithms for deriving imaging signatures predictive of clinical outcome and could similarly be used for a variety of radiomic and radiogenomic analyses.
format Online
Article
Text
id pubmed-7113126
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-71131262021-03-19 Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma Fathi Kazerooni, Anahita Akbari, Hamed Shukla, Gaurav Badve, Chaitra Rudie, Jeffrey D. Sako, Chiharu Rathore, Saima Bakas, Spyridon Pati, Sarthak Singh, Ashish Bergman, Mark Ha, Sung Min Kontos, Despina Nasrallah, MacLean Bagley, Stephen J. Lustig, Robert A. O’Rourke, Donald M. Sloan, Andrew E. Barnholtz-Sloan, Jill S. Mohan, Suyash Bilello, Michel Davatzikos, Christos JCO Clin Cancer Inform ORIGINAL REPORTS PURPOSE: To construct a multi-institutional radiomic model that supports upfront prediction of progression-free survival (PFS) and recurrence pattern (RP) in patients diagnosed with glioblastoma multiforme (GBM) at the time of initial diagnosis. PATIENTS AND METHODS: We retrospectively identified data for patients with newly diagnosed GBM from two institutions (institution 1, n = 65; institution 2, n = 15) who underwent gross total resection followed by standard adjuvant chemoradiation therapy, with pathologically confirmed recurrence, sufficient follow-up magnetic resonance imaging (MRI) scans to reliably determine PFS, and available presurgical multiparametric MRI (MP-MRI). The advanced software suite Cancer Imaging Phenomics Toolkit (CaPTk) was leveraged to analyze standard clinical brain MP-MRI scans. A rich set of imaging features was extracted from the MP-MRI scans acquired before the initial resection and was integrated into two distinct imaging signatures for predicting mean shorter or longer PFS and near or distant RP. The predictive signatures for PFS and RP were evaluated on the basis of different classification schemes: single-institutional analysis, multi-institutional analysis with random partitioning of the data into discovery and replication cohorts, and multi-institutional assessment with data from institution 1 as the discovery cohort and data from institution 2 as the replication cohort. RESULTS: These predictors achieved cross-validated classification performance (ie, area under the receiver operating characteristic curve) of 0.88 (single-institution analysis) and 0.82 to 0.83 (multi-institution analysis) for prediction of PFS and 0.88 (single-institution analysis) and 0.56 to 0.71 (multi-institution analysis) for prediction of RP. CONCLUSION: Imaging signatures of presurgical MP-MRI scans reveal relatively high predictability of time and location of GBM recurrence, subject to the patients receiving standard first-line chemoradiation therapy. Through its graphical user interface, CaPTk offers easy accessibility to advanced computational algorithms for deriving imaging signatures predictive of clinical outcome and could similarly be used for a variety of radiomic and radiogenomic analyses. American Society of Clinical Oncology 2020-03-19 /pmc/articles/PMC7113126/ /pubmed/32191542 http://dx.doi.org/10.1200/CCI.19.00121 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/
spellingShingle ORIGINAL REPORTS
Fathi Kazerooni, Anahita
Akbari, Hamed
Shukla, Gaurav
Badve, Chaitra
Rudie, Jeffrey D.
Sako, Chiharu
Rathore, Saima
Bakas, Spyridon
Pati, Sarthak
Singh, Ashish
Bergman, Mark
Ha, Sung Min
Kontos, Despina
Nasrallah, MacLean
Bagley, Stephen J.
Lustig, Robert A.
O’Rourke, Donald M.
Sloan, Andrew E.
Barnholtz-Sloan, Jill S.
Mohan, Suyash
Bilello, Michel
Davatzikos, Christos
Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma
title Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma
title_full Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma
title_fullStr Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma
title_full_unstemmed Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma
title_short Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma
title_sort cancer imaging phenomics via captk: multi-institutional prediction of progression-free survival and pattern of recurrence in glioblastoma
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113126/
https://www.ncbi.nlm.nih.gov/pubmed/32191542
http://dx.doi.org/10.1200/CCI.19.00121
work_keys_str_mv AT fathikazeroonianahita cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT akbarihamed cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT shuklagaurav cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT badvechaitra cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT rudiejeffreyd cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT sakochiharu cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT rathoresaima cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT bakasspyridon cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT patisarthak cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT singhashish cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT bergmanmark cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT hasungmin cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT kontosdespina cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT nasrallahmaclean cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT bagleystephenj cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT lustigroberta cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT orourkedonaldm cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT sloanandrewe cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT barnholtzsloanjills cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT mohansuyash cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT bilellomichel cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma
AT davatzikoschristos cancerimagingphenomicsviacaptkmultiinstitutionalpredictionofprogressionfreesurvivalandpatternofrecurrenceinglioblastoma